Key result
The Formulary Monograph Service provides researched monographs on newly released drugs and agents in late Phase III trials, including target drug utilization evaluations.
Answers are grounded in this paper and cite their sources.
Aids timely formulary decisions for emerging agents; extends evidence resources for clinicians and researchers evaluating late-phase trials.
Each month, subscribers to The Formulary ® Monograph Service receive five to six researched monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board called The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The May 2000 Formulary monographs are linezolid, pneumococcal 7-valent conjugate vaccine, apomorphine, levobetaxolol HCl, mequinol 2% and tretinoin 0.1% topical solution. The DUE is on dexmedetomidine.
No takes yet. Share an insight, caveat, or question.
Cada et al. (2000) reported an editorial. Dofetilide was evaluated. The Formulary Monograph Service provides researched monographs on newly released drugs and agents in late Phase III trials, including target drug utilization evaluations.
Synapse has enriched 10 related papers. Consider them for comparative context: